The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting.

According to a retrospective cohort study, certolizumab, a pegylated tumor necrosis factor (TNF) blocker, is most commonly prescribed to patients with Crohn disease (CD) who were previously non-responsive or intolerant of other anti-TNF therapies. Findings were presented at the AIBD 2019 Annual Meeting in Orlando, Florida.

To better understand the real-world prescribing patterns of certolizumab, researchers collected data from a large multicenter gastroenterology private practice dating back to 2008, when the drug was initially approved. Specific assessments included patient demographics, diagnosis, treatment history and the reason for certolizumab use (ie, first-line therapy, anti-TNF failure or intolerance, payor requirements, and pregnancy considerations).

The analysis included 59 CD patients (71% female), 46 of which had private insurance. Patients were treated with certolizumab for a median duration of 26 months (IQR 9-50 months). The majority of patients were biologic-experienced (85%); common prior biologic treatment included infliximab and adalimumab

Related Articles

The most common reason for certolizumab use was found to be prior biologic non-response or intolerance (66%) followed by pregnancy considerations (14%), and payor/cost considerations (10%). Among the group, 44% of patients continue to be treated with certolizumab with a median duration of 48 months; 1 patient had been receiving treatment for almost 10 years.

Based on their findings, the authors concluded “that patients treated with certolizumab have high treatment persistence, and may successfully remain on therapy long-term.” 


Ritter, T et al; Real-World Prescribing Patterns of Certolizumab in the Treatment of Crohn’s Disease. Presented at the 2019 AIBD Annual Meeting on December 12-14 in Orlando, FL.